The aim of this course is to assist Cervical Sample Taker Trainees to maintain high standards of sample taking in accordance with local and national standards. The guidance was updated in 2020 and our initial training sessions include the following:
Trainees will receive initial theory and practical training with our Clinical Educators before completing the rest of the programme by undertaking supported procedures in practice with their Mentor. The whole programme can take up to 6 months to complete, but can take as little as 6 weeks if there are sufficient appointments available to the Trainee.
Devon Training Hub provides a detailed programme of work to follow, a Training Portfolio and Training Handbook, and professional support for Sample Taker Trainees and their Mentors throughout the programme. When the Trainee Sample Taker has completed the programme we allocate an independent External Assessor to liaise with the Trainee and complete a Final Clinical Assessment.
Course details:
Tuesday 11 January 2022 - 12:30pm - 1:30pm
Mentor Introduction - Mandatory Training for Mentors of Trainees in Practice
Tuesday 18 January 2022 - 9:30am - 4pm
Face to Face Theory for Trainee Sample Takers at Lostwithiel Community Centre, PL22 0HE
Tuesday 25 January 2022 - 9:30am - 4pm
Face to Face Theory and Practical for Trainee Sample Takers at Lostwithiel Community Centre, PL22 0HE
We would like to invite you to join us for a webinar at 1-2pm on the 17th November 2021, covering:
The webinar will be aimed at all non-clinical staff (and is also relevant for HCAs and social prescribers) within your practice and will help you to meet the requirements of the new Long Covid DES:
“Practice staff are required to have the knowledge, as appropriate to their role, to identify, assess, refer and support patients with Long COVID”
The presenter is:
Rachel Byford – Regional Lead for Long Covid, NHSEI
If you would like to attend this informative webinar please click on the link to complete the Microsoft application form
We would like to invite you to join us for a webinar at 1-2pm on 4 November, 2021, covering:
The webinar will be aimed at all non-clinical staff (and is also relevant for HCAs and social prescribers) within your practice and will help you to meet the requirements of the new Long Covid DES:
“Practice staff are required to have the knowledge, as appropriate to their role, to identify, assess, refer and support patients with Long COVID”
The presenter is:
Rachel Byford – Regional Lead for Long Covid, NHSEI
If you would like to attend this informative webinar please click on the link to complete the Microsoft application form
The 10th annual Diabetes in Pregnancy UK Conference is taking place online on Tuesday, 16 November, from 1.30pm – 4.15pm. Professor Jonathan Valabhji OBE, National Clinical Director for Diabetes and Obesity, will open the Conference outlining Gestational Diabetes and the National Prevention programme. Other key topics being covered include a technology journey on GDM health, including the digital divide, CGM, diversity and exclusion and the National Diabetes in Pregnancy Data. This year will also focus on important role of midwifery and multi-disciplinary teams and continuity of care, and we will be linking in with the Royal College of Midwifery. There is a fee of £24 per delegate to attend and the event is CPD accredited. For further information and to register please go to https://www.diabetes.org.uk/professionals/conferences/pregnancy-2021
Men's Health: Update on Prostate Cancer - 17th June 2021 - 12.30pm to 1.30pm
Prostate cancer now most commonly diagnosed cancer in England
There were 49,029 diagnoses of prostate cancer in 2018, meaning prostate cancer overtakes breast cancer as the most common cancer in England.
Too many men are diagnosed late
(approx 20% stage 4, no longer prostate confined, 17% at latest NPCA report)
Stage 1 The tumour is contained in the prostate. The tumour is too small to be felt on DRE or to be seen on a scan.
Stage 2 The tumour is still contained in the prostate, but can be felt on DRE
Stage 3 The tumour has started to break through the outer capsule of the prostate and may be in the seminal vesicles.
Stage 4 The tumour has spread outside the prostate. It may have spread to areas such as the bladder or rectum. Or it may have spread further, for example to the bones.
One-year net survival for prostate cancer is highest for patients diagnosed at Stage 1, Stage 2, and lowest for those diagnosed at Stage 4, 100% of patients diagnosed at Stage 1 & Stage 2 survived their disease for at least one year, compared to 88% of patients diagnosed at Stage 4.
Five-year net survival decreases from Stage 3 (96%) to Stage 4 (49%), a difference of 47 percentage points.
The presentation will focus on early diagnosis, advances in treatment and dealing with complications at follow up.
The Child in Context: Could this be Arthritis?
Date: 6th July 2021
Time: 13:00 - 14:00
Suitable for GPs
Aim:
To be achieved through these objectives:
Service development by closer liaison between primary care and hospital to improve patient pathways
Opportunity to discuss difficult or interesting cases
Learning outcomes i.e. by the end of this activity, attendees should be able to:
Men's Health: Cancer and the Heart - 7th July 2021 - 12.30pm to 1.30pm
Cancer and the heart
Improvements in cancer treatment and earlier diagnosis have contributed to increased survival. Unfortunately, many cancer treatments carry an increased risk of cardiovascular disease (CVD). The CVD risk is of particular consideration in an ageing population of cancer survivors who may have co-morbidities which also exacerbate this risk, and in adult survivors of childhood cancer treatment who may present with CVD symptoms at a relatively young age. Heart disease following cancer treatment may be the result of direct CV damage, caused by the treatment or may be due to the development of cancer treatment-related CV risk factors.
Working with other professionals when necessary, GPs, community pharmacists and nurses are in a good position to follow-up people affected by cancer to ensure that CV risks are monitored, preventative action is taken, CVD is diagnosed and appropriate treatments are initiated.
Men's Health:Top Tips on PSA Testing - 13th July 2021 - 12.30pm to 1.30pm
Top tips on PSA testing
A huge topic in itself. First establish the man’s main concern. The PSA test should certainly not be done without adequate counselling. A quick summary of the facts may be as follows: large trials have shown that use of the PSA test results in fewer men dying of prostate cancer, but not fewer deaths overall. Its use can result in detection of prostate cancer cases that may never have caused any problems, with investigations and treatments that have risks of side effects (overdetection, overtreatment), though this is improving.
It can be helpful to direct men to an information leaflet from the Prostate Cancer Risk Management
The Prostate Cancer Risk Management Programme provides good advice to professionals and patients
“The PSA Test is available free to any well man over 50 who requests it”
Plus:
Younger men with high risk at the GP’s clinical judgement
Other factors influencing a high PSA
10 years’ life expectancy important to consider
Sensitivity and specificity, currently being reviewed by DOH regarding national screening programme
Men's Health: Management of Lower Urinary Tract Symptoms in Men - 14th September 2021 - 12.30pm to 1.30pm
Lower urinary tract symptoms in men
The skill is making the right diagnosis and providing the right treatment.
This course is being run as an online training course. Details of how to join the meeting will be emailed to you closer to the event.
For more information please contact devon.traininghub@nhs.net
Men's Health: Erectile Dysfunction- 5th October 2021 - 12.30pm to 1.30pm
Erectile dysfunction
Erectile dysfunction (ED) is defined as the inability to achieve or maintain an erection for satisfactory sexual performance. The prevalence of ED has been estimated as nearly 40% of men >40 years of age although these figures are contested. ED increases in frequency with age and is estimated to affect 15% of men aged 40–50 years, 45% of men in their 60s and 70% of men older than 70 years. Successful erection is a complex system involving reflex action (peripheral nerves and spinal cord), the limbic system (psychogenic stimuli) and the release of nitric oxide. Adequate levels of testosterone are required, and hence an intact hypothalamic/ pituitary/testicular axis. Hence, ED can result from disease or treatment that produces hormonal deficiency, neurological impairment, problems with penile blood flow, disorders of tissue mechanics, and psychologic issues.
Endothelial dysfunction is one of the first changes in CVD. ED and CVD share many common risk factors including age, hypertension, diabetes, insulin resistance, smoking, increased body mass index, cholesterol and low high-density lipoprotein, metabolic syndrome, sedentary lifestyle and depression. Numerous studies and meta-analyses have confirmed the association between ED and CAD. ED is associated with asymptomatic CAD. ED precedes CAD and referral for CAD by periods ranging from 2 to 5 years. Compared with controls, patients with ED have a higher risk for total CV events (44%), myocardial infarction (MI) (60%) and all-cause mortality (25%). ED also appears to be a marker of the severity of CVD with ED associated with increased risk of CVD mortality with a HR 1.48 in a large meta-analysis of 12 prospective cohortstudies.
There are many effective treatments.
This course is being run as an online training course. Details of how to join the meeting will be emailed to you closer to the event.
For more information please contact devon.traininghub@nhs.net
